Leonard Kalman

2.5k total citations · 1 hit paper
29 papers, 2.0k citations indexed

About

Leonard Kalman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Leonard Kalman has authored 29 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Leonard Kalman's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Leonard Kalman is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (8 papers) and Cancer Treatment and Pharmacology (5 papers). Leonard Kalman collaborates with scholars based in United States, Switzerland and Germany. Leonard Kalman's co-authors include Mark G. Kris, John D. Hainsworth, Jeffrey Crawford, Vincent A. Miller, F. Gamza, Daniel D. Karp, Jin Soo Lee, Luz Hammershaimb, Everett E. Vokes and Frank V. Fossella and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Gynecologic Oncology.

In The Last Decade

Leonard Kalman

28 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 1.1k citations Frank V. Fossella, Russell F. DeVore et al. Journal of Clinical Oncology profile →

Peers

Leonard Kalman

ONCOL

PRM

SURGE

MB

PFM

James D. Ahlgren United States

Anna Maria Frezza Italy

Lemuel Herrera United States

N. Davidson United Kingdom

E. Maillard France

Yusuke Onozawa Japan

Albiruni Ryan Abdul Razak Canada

Yasser Khafaga Saudi Arabia

Fausto Barbieri Italy

Silvia Mezi Italy

James D. Ahlgren United States

Leonard Kalman

1.1k ×0.7

ONCOL

359 ×0.3

PRM

343 ×1.0

SURGE

192 ×0.6

MB

218 ×1.0

PFM

Citations per year, relative to Leonard Kalman Leonard Kalman (= 1×) peers James D. Ahlgren

Countries citing papers authored by Leonard Kalman

Since Specialization

Citations

This map shows the geographic impact of Leonard Kalman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard Kalman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard Kalman more than expected).

Fields of papers citing papers by Leonard Kalman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard Kalman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard Kalman. The network helps show where Leonard Kalman may publish in the future.

Co-authorship network of co-authors of Leonard Kalman

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard Kalman. A scholar is included among the top collaborators of Leonard Kalman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard Kalman. Leonard Kalman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Case, Delvyn C., et al.. (2007). Community-Based Trial of R-CHOP and Maintenance Rituximab for Intermediate- or High-Grade Non-Hodgkin Lymphoma with First-Cycle Filgrastim for Older Patients. Clinical Lymphoma & Myeloma. 7(5). 354–360. 16 indexed citations

2.

Hainsworth, John D., et al.. (2005). Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Gynecologic Oncology. 97(1). 200–205. 2 indexed citations

3.

Birch, Robert, et al.. (2004). Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4622–4622. 40 indexed citations

4.

Birch, Robert, et al.. (2004). Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4622–4622. 2 indexed citations

5.

Meluch, Anthony A., F. Anthony Greco, James R. Gray, et al.. (2003). Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer. The Cancer Journal. 9(4). 251–260. 92 indexed citations

6.

Gregory, Stephanie A., Delvyn C. Case, Linda D. Bosserman, et al.. (2003). Fourteen-Day CHOP Supported with Granulocyte Colony-Stimulating Factor in Patients with Aggressive Non-Hodgkin's Lymphoma: Results of a Phase II Study. Clinical Lymphoma. 4(2). 93–98. 10 indexed citations

7.

Kalman, Leonard, L Bertoli, Lee Ratner, et al.. (2003). 246 Preliminary data on weekly irinotecan with continuous oral administration of capecitabine in metastatic colorectal cancer. European Journal of Cancer Supplements. 1(5). S76–S76. 2 indexed citations

8.

Hainsworth, John D., James R. Gray, Lisa H. Morrissey, et al.. (2002). Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology. 20(13). 2937–2942. 7 indexed citations

9.

Hainsworth, John D., Howard A. Burris, Denise A. Yardley, et al.. (2001). Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology. 19(15). 3500–3505. 132 indexed citations

10.

Greco, Frank A., Howard A. Burris, James R. Gray, et al.. (2000). Carcinoma of unknown primary site. Cancer. 89(12). 2655–2660. 59 indexed citations

11.

Burris, Howard A., John D. Hainsworth, Joan B. Erland, et al.. (2000). Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.. PubMed. 27(1 Suppl 2). 9–13. 12 indexed citations

12.

Fossella, Frank V., Russell F. DeVore, Jeffrey Crawford, et al.. (2000). Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. Journal of Clinical Oncology. 18(12). 2354–2362. 1124 indexed citations breakdown →

13.

Hainsworth, John D., Howard A. Burris, Joan B. Erland, et al.. (1999). Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 85(6). 1269–1276. 35 indexed citations

14.

Hainsworth, John D., Joan B. Erland, Leonard Kalman, Marshall T. Schreeder, & F. Anthony Greco. (1997). Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.. Journal of Clinical Oncology. 15(6). 2385–2393. 97 indexed citations

15.

Hainsworth, John D., J. R. Gray, Steven L. Stroup, et al.. (1997). Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.. Journal of Clinical Oncology. 15(12). 3464–3470. 70 indexed citations

16.

Weaver, CH, West Wh, Thomas Alberico, et al.. (1997). Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplantation. 19(7). 661–670. 24 indexed citations

17.

Hainsworth, John D., et al.. (1997). 17 Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): A report on 117 patients (PTS) treated by the Minnie Pearl cancer research network. Lung Cancer. 18. 7–7. 3 indexed citations

18.

Kalman, Leonard. (1994). High Dose Chemotherapy with Peripheral Blood Stem Cell Support for High Risk Stage II and Stage III Breast Cancer. 5 indexed citations

19.

Kris, Mark G., R. Gralla, Leonard Kalman, et al.. (1985). Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Lung Cancer. 1(3-4). 79–79. 70 indexed citations

20.

Kris, Mark G., Richard J. Gralla, Leslie B. Tyson, et al.. (1985). Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 55(3). 527–534. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact